Form M Crystalline Intermediate for Palbociclib
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing polymorphic forms of palbociclib intermediates face challenges in filterability, drying efficiency, and purity, particularly when scaled up for industrial production.
Innovation Solution
A novel crystalline Form M of Formula-2 is developed, characterized by specific X-ray diffraction peaks and prepared through a process involving dissolution, heating, optional seeding, slow cooling, and isolation, using solvents like alcohols and tetrahydrofuran, which enhances filterability and purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If existing polymorphic forms of palbociclib intermediates are used, then the synthesis process can proceed, but filterability and drying efficiency are poor
Solution Approach 1:
The patent applies parameter changes by discovering and utilizing a new polymorphic form (Form M) of the intermediate compound, which has different physical properties including improved filterability and drying characteristics compared to previously known forms. This resolves the contradiction by changing the crystalline structure parameters of the material itself.
Solution Approach 2:
The patent employs a eutectic mixture as a transient solvent system that facilitates the formation of the desired polymorphic form during crystallization, then is removed in the filtration step. The eutectic mixture serves its purpose temporarily and is discarded with the mother liquor, enabling the isolation of the filterable crystalline form.
2Manufacturing precision
If existing polymorphic forms are used, then synthesis can proceed, but purity is insufficient at 99.0%
Solution Approach 1:
The patent achieves high purity (99.0%) by changing to a new polymorphic form (Form M) that crystallizes with superior purity characteristics. The different crystal lattice structure of Form M inherently excludes impurities more effectively, enabling high-purity product at industrial scale without requiring additional purification steps.
Solution Approach 2:
The patent employs preliminary action by using a eutectic mixture to pre-condition the crystallization process, ensuring that the intermediate forms into the desired high-purity polymorphic form before isolation. This preliminary solvent selection sets up the crystallization to favor the formation of pure Form M crystals.
3Productivity
If existing polymorphic forms are used, then the process is established, but the process cannot be effectively scaled up for industrial production
Solution Approach 1:
The patent enables effective scale-up by changing to Form M, which has superior filterability characteristics that remain consistent across different production scales. The crystalline form's physical properties allow for efficient filtration and handling whether produced in small or large quantities, resolving the scalability issue.
Solution Approach 2:
The eutectic mixture serves as a temporary, disposable solvent system that facilitates crystallization during the process, then is easily removed during filtration. This approach enables scalable production because the eutectic mixture can be efficiently separated at any scale, leaving behind the filterable Form M crystals.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel Form M of Formula-2 improves filterability, drying efficiency, and achieves a high purity of 99.0%, facilitating more effective industrial-scale preparation of palbociclib with enhanced yield and quality.
Implementation Method 1
crystalline Form M of Formula-2 may be prepared by a process that includes the steps of: a) dissolving a compound of Formula-2 in a solvent to form a reaction mixture; b) heating the reaction mixture; c) optionally adding a seed of Form M of Formula-2; d) slowly cooling the reaction mixture; and e) isolating crystalline Form M of Formula-2
Data Source
AI summary
The present disclosure provides a novel polymorph of an intermediate useful in the preparation of palbociclib. The polymorph has enhanced properties that influence process ability of the intermediate and synthesis of palbociclib.